Retatrutide vs Tirzepatide: Receptors, PK and Trial Data

Retatrutide and tirzepatide are both once-weekly lipidated peptides from the same developer, and both act on the GIP and GLP-1 receptors. The difference is a third target: retatrutide also activates the glucagon receptor. That single pharmacological change is the basis of every other comparison, from preclinical energy expenditure to trial design.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

Tirzepatide: dual GIP/GLP-1 agonist. Retatrutide: triple GIP/GLP-1/glucagon agonist.
Similar half-lives: about 5 days (tirzepatide) and about 6 days (retatrutide).
Tirzepatide is licensed; retatrutide is investigational, with phase 3 data from 2026.
No head-to-head trial exists, so cross-trial numbers are not directly comparable.
Both are handled as lipidated, aggregation-prone peptides in the lab.

Side-by-side comparison

	Tirzepatide	Retatrutide
Development code	LY3298176	LY3437943
Receptors	GIPR, GLP-1R	GIPR, GLP-1R, GCGR
Structure	39 aa, GIP-based, Aib2/Aib13, C20 diacid on Lys20; 4813.53 Da	Single lipidated peptide (structure per developer publications)
Human half-life	~5 days (Schneck et al., 2024)	~6 days (Urva et al., 2022)
Discovery paper	Coskun et al., 2018	Coskun et al., 2022
Status	Approved for specific indications	Investigational

Both are available as lyophilized research peptides: retatrutide and tirzepatide, in 5–60 mg vials.

Pharmacology: what the third receptor changes

Tirzepatide was designed to test whether adding GIP agonism improves on selective GLP-1 receptor agonists; in vitro it activates both receptors and in mice it reduced food intake and body weight (Coskun et al., 2018). Retatrutide shows balanced glucagon and GLP-1 receptor activity in vitro, with greater GIP receptor activity. In obese mice, glucagon-receptor-mediated increases in energy expenditure added to the intake-reducing effects of GIP and GLP-1 agonism (Coskun et al., 2022). In short, tirzepatide works mainly on the intake side of energy balance in these models, while retatrutide is designed to act on both intake and expenditure.

Trial endpoints (separate trials, not head-to-head)

	Tirzepatide: SURMOUNT-1	Retatrutide: phase 3 obesity
Participants	2539 adults, obesity/overweight, no diabetes	2339 adults, obesity, no diabetes
Duration	72 weeks	80 weeks
Mean % body-weight change (dose groups)	−15.0% to −20.9%	−17.6% to −25.0%
Placebo	−3.1%	−3.9%
Most common adverse events	Gastrointestinal	Gastrointestinal, dose-related
Reference	Jastreboff et al., 2022	Jastreboff et al., 2026

Different durations (72 vs 80 weeks), populations and estimands mean these ranges should not be read as a direct ranking. A head-to-head trial would be needed to compare the two molecules properly.

Pharmacokinetics

Both molecules achieve weekly exposure through albumin binding of a fatty acid side chain. Tirzepatide’s population PK model (19 pooled studies) gives a half-life of about 5 days with a two-compartment structure (Schneck et al., 2024). Retatrutide’s phase 1b study in type 2 diabetes reported dose-proportional pharmacokinetics and a half-life of about 6 days (Urva et al., 2022). See retatrutide half-life and tirzepatide half-life.

Lab handling compared

Aspect	Both peptides
Supplied as	Lyophilized powder
Storage (powder)	−20 °C, sealed, dark
Reconstitution	Slow addition, gentle swirling; lipidated peptides can self-associate
Solution storage	2–8 °C; avoid freeze–thaw
Identity check	MS: both ~4.7–4.8 kDa, so high-resolution MS or HPLC retention time distinguishes them reliably

Compound-specific guides: reconstituting retatrutide and reconstituting tirzepatide. Concentrations: peptide reconstitution calculator.

Why the glucagon component matters for study design

Because glucagon receptor activation raises hepatic glucose output and influences liver lipid metabolism, retatrutide research often measures endpoints that are less central in tirzepatide studies, such as liver fat and energy expenditure. A phase 2a trial of retatrutide in metabolic dysfunction-associated steatotic liver disease illustrates this focus (Sanyal et al., 2024). For laboratory comparisons, using both molecules side by side, ideally with a GLP-1R-selective reference, is a practical way to isolate what the third receptor contributes.

Open questions

Would a head-to-head trial confirm the differences suggested by separate trials?
How do the two compare on lean-mass preservation, which a 2025 network meta-analysis examined across incretin agonists and co-agonists?
Does glucagon receptor agonism change long-term safety relative to dual agonism?

For laboratory buyers, the practical difference is mostly in the identity check: the two peptides have similar masses and chromatographic behaviour, so the certificate of analysis should report an MS result that matches the specific molecule.

Related research

Frequently asked questions

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors (GIP and GLP-1). Retatrutide activates three (GIP, GLP-1 and glucagon). Both are lipidated peptides developed by Eli Lilly for once-weekly administration.

Is retatrutide better than tirzepatide?

There is no published head-to-head trial. Cross-trial comparisons are unreliable because populations, durations and analysis methods differ. Each molecule has to be judged on its own trial data.

Do retatrutide and tirzepatide have similar half-lives?

Yes, broadly. Tirzepatide’s human half-life is about 5 days; retatrutide’s was about 6 days in a phase 1b study.

What does glucagon receptor activity add?

In preclinical work, glucagon receptor agonism added an increase in energy expenditure to the reduced food intake driven by GIP and GLP-1 receptor activity.

Are both approved medicines?

Tirzepatide is approved in the US and EU for specific indications. Retatrutide is investigational, with phase 3 results published in 2026.

References

Karakasis P, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025. PMID: 39719170 https://pubmed.ncbi.nlm.nih.gov/39719170/
Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PMID: 38858523 https://pubmed.ncbi.nlm.nih.gov/38858523/
Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. PMID: 30473097 https://pubmed.ncbi.nlm.nih.gov/30473097/
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022. PMID: 35985340 https://pubmed.ncbi.nlm.nih.gov/35985340/
Schneck K, et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38356317 https://pubmed.ncbi.nlm.nih.gov/38356317/
Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PMID: 36354040 https://pubmed.ncbi.nlm.nih.gov/36354040/
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024 https://pubmed.ncbi.nlm.nih.gov/35658024/
Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954 https://pubmed.ncbi.nlm.nih.gov/42814954/